Prostate cancer: diagnosis and management


Key events during the development of the guidance

Date Update
8 January 2014 CG175 Prostate cancer (update of CG58) publishes
12 March 2012 The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table. The Guideline Development Group (GDG) oversees the development process.
5 March 2012 In line with the draft methods for developing quality standards, the development of the quality standard will be the responsibility of a separate group. This will include topics experts, some of whom will be drawn from the Guideline Development Group. The clinical guideline scope will form the basis from which the clinical guideline will be developed and the quality standard scope will inform the development of the quality standard, which will be developed following completion of the clinical guideline.
28 November 2011

The draft scope is out for consultation with stakeholders. The scope defines what aspects of care the guideline will cover and to whom it will apply. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed, by the deadline shown.